DKM 2-93 not only impairs pancreatic cancer cell survival in PaCa2, but also Panc1 cells with 50 % effective concentration values of 90 and 30 μM, respectively.
In vivo
DKM 2-93 daily treatment significantly impairs tumor growth of PaCa2 cells in vivo in tumor xenograft studies in immune-deficient mice without causing any weight loss or overt toxicity.